Other active invasive malignancies, with the exception of non-melanoma skin cancer and breast cancer (if without evidence of disease  years after completion of treatment)
No other concurrent invasive malignancies treated for the past year (localized prostate cancer or early stage skin cancer are not exclusion criteria)
Other invasive cancer diagnosis within the past  years other than non-melanoma skin cancer
Patients with a history within the last  years of another invasive malignancy (localized non-melanoma skin and bladder cancers are allowed).
Currently active second malignancy or past history of malignancies diagnosed within the last  years that require active therapy and/or in remission with life expectancy of <  years, with the exception of resected non-melanoma skin cancers, non-muscle invasive bladder cancer, stage I head and neck cancer, or stage I colorectal cancer
Presence of another invasive malignancy, which required systemic therapy within  months of protocol enrollment, except for resected skin cancers or prostate cancer that is in remission
Patients must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required)
Diagnosis of other invasive malignancies within the preceding  years prior to screening with > % likelihood of relapse within the next  years, except non-melanoma skin cancer and non-muscle invasive urothelial cancer
Patients diagnosed with an invasive cancer within  years prior to starting protocol therapy with the following exceptions: non-melanoma skin cancers, in-situ cancers, and prostate cancer Gleason =< to  (under surveillance or treated)
Patients diagnosed with an invasive cancer within  years prior to starting protocol therapy with the following exceptions: non-melanoma skin cancers, in-situ cancers, and prostate cancer gleason =<  (under surveillance or treated)
Patients must not have other active invasive malignancies within the past  years (with the exception of non-melanoma skin cancers) (for CRPC cohort only)
Patients must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required)
No active invasive malignancy in the past  years other than non-melanoma skin cancer; cancers that are in-situ are not considered invasive
Invasive solid tumor within  years; non-melanoma skin cancer or in situ malignancies are allowed
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years
No other cancer in previous  years with the exception of non-invasive skin cancers
Evidence of invasive anal, vulva, vaginal, or cervical carcinoma; prior loop electrosurgical excision procedure (LEEP) or ablative treatment within  months prior to study entry; other invasive malignancies, with the exception of non-melanoma skin cancer, within the last  years
History of another invasive cancer within  years before screening, with the exception of fully treated cancers with a remote probability of recurrence
Must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers or non-invasive bladder cancer).
Other invasive malignancies within the last  years, except non- melanoma skin cancer and localized cured prostate and cervical cancer;
Active invasive cancer other than the one of the three cancers in this study; patients with active non-invasive cancers (such as non-melanoma skin cancer, superficial cervical and bladder and prostate cancer with PSA level < .) are not excluded
No prior history of non-breast invasive malignancies in the past  year
Presence of other active cancers, or history of treatment for invasive cancer within the past  years; patients with stage I cancer who have received definitive local treatment, and are considered unlikely to recur are eligible; all patients with previously treated in situ carcinoma (i.e. noninvasive) are eligible, as are patients with history of non-melanoma skin cancer and patients with localized prostate cancer on watch and wait
Patients must not have other active invasive malignancies within the past  years (with the exception of non-melanoma skin cancers) or life threatening illnesses
Presence of other active cancers, or history of treatment for invasive cancer ?years. Patients with Stage I cancer who have received definitive local treatment at least  years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
Patients must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers, non-invasive bladder cancer or localized prostate cancer for whom systemic therapy is not required)
No active invasive malignancy in the past  years other than non-melanoma skin cancer; cancers that are in-situ are not considered invasive
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer within the last five years
Presence of other active cancers, or history of treatment for invasive cancer ? years
History of another invasive malignancy in the last two years; adequately treated non-invasive, non-melanoma skin cancers as well as in situ carcinoma of the cervix will be allowed
Patients must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers, localized prostate cancer, carcinoma in situ of the cervix and non-invasive bladder cancer that has had successful curative treatment)
Previously diagnosed with another malignancy, within the past two years with the exception of non-melanoma skin cancers or non-invasive bladder cancer
Patients must not have other invasive malignancies within the past  years (with the exception of non-melanoma skin cancers or non-invasive bladder cancer)
No history of a previous invasive cancer in the last five years with the exception of minimally invasive non-melanoma skin cancer.
History of other invasive cancer in the previous  years other than minimally invasive non-melanoma skin cancer.
No concurrently active second invasive malignancies except non-melanoma skin cancer
Other cancers (excluding non-melanoma skin cancer) diagnosed within  years prior to index lesion, including concurrent invasive cancer diagnosis and up to the present time of participants approach to invitation into the study
Development of invasive subsequent malignancy after HCT other than non-melanoma skin cancer, in the past two years
Patients may not have a history of other invasive malignancies within the last five years, with the exception of non-melanoma skin cancer or stage A endometrioid adenocarcinoma of the uterus
Invasive cancer within the past five years except non-melanoma skin cancer
History of invasive cancer within the past  years, with the exception of excised and cured non-melanoma skin cancer or carcinoma in situ of the cervix
Invasive cancer within the past five years except non-melanoma skin cancer
